Abstract:BACKGROUND:Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary tumor syndrome with an incidence of approximately 1/36,000. VHL disease-associated clear cell renal cell carcinoma (ccRCC) is the most common congenital RCC. Although recent advances in treating RCC have improved the long-term prognosis of patients with VHL disease, kidney cancer is still the leading cause of death in these patients. Therefore, finding new targets for diagnosing and treating VHL disease-associated ccRCC is still essential.METHODS:In this study, we collected matched tumor tissues and normal samples from 25 patients with VHL disease-associated ccRCC, diagnosed and surgically treated in the Department of Urology, Peking University First Hospital. After screening, we performed whole genome bisulfite sequencing (WGBS) on 23 pairs of tissues and RNA-seq on 6 pairs of tissues. And we also compared the VHL disease-associated ccRCC transcriptome data with the sporadic ccRCC transcriptome data from the The Cancer Genome Atlas (TCGA) public database RESULTS: We found that the methylation level of VHL disease-associated ccRCC tumor tissues was significantly lower than that of normal tissues. The tumor tissues showed a difference in the copy number of 3p loss and 5q and 7q gain compared with normal tissues. We integrated RNA-seq and WGBS data to reveal methylation candidate genes associated with VHL disease-associated ccRCC; our results showed 124 hypermethylated and downregulated genes, and 245 hypomethylated and upregulated genes. By comparing the VHL disease-associated ccRCC transcriptome data with the sporadic ccRCC transcriptome data from the TCGA public database, we found that the major pathways of differential gene enrichment differed between them.CONCLUSIONS:Our study mapped the multiomics of copy number variation, methylation and mRNA level changes in tumor and normal tissues of clear cell renal cell carcinoma with VHL syndrome, which provides a solid foundation for the mechanistic study, biomarker screening, and therapeutic target discovery of clear cell renal cell carcinoma.

AB174. VHL Protein: a New Therapeutic Target of Renal Cell Carcinoma

VHL Loss Predicts Response to Aurora Kinase A Inhibitor in Renal Cell Carcinoma Cells.

Abnormality of VHL Gene and VEGF Expression in Primary Renal Cell Carcinoma

The Mutation and Abnormal Methylation of VHL Tumor-Suppressor Gene in Primary Renal Cell Carcinoma

Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer.

[Frequent Somatic Mutations of the Von Hippel-Lindau (VHL) Tumor Suppressor Gene and Its Meaning in Sporadic Human Renal Clear Cell Carcinoma].

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated Ccrcc.

[Frequent Somatic Mutations of the Von Hippel-Lindau Tumor Suppressor Gene in Primary Sporadic Human Renal Clear Cell Carcinomas].

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells

VHL enhances 9-cis-retinoic acid treatment by down-regulating retinoid X receptor α in renal cell carcinomas.

Mutation of Von Hippel-Lindau Tumor Suppressor Gene in Sporadic Clear Renal Cell Carcinoma and Its Significance

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway

VHLmissense Mutation Delineate Aggressive Clear Cell Renal Cell Carcinoma Subtype with Favorable Immunotherapeutic Response

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma

[Analysis of Biallelic Inactivation of the Von Hippel-Lindau Tumor Suppressor Gene VHL in Patients of Renal Cell Carcinoma Patient].

VHL Substrate Transcription Factor ZHX2 As an Oncogenic Driver in Clear Cell Renal Cell Carcinoma

POLR2A Drives Tumor Cell Aggressive in Both VHL and PBRM1 Mutation Renal-Cell Carcinoma

VHL Ser65 Mutations Enhance HIF2α Signaling and Promote Epithelial-Mesenchymal Transition of Renal Cancer Cells

AB175. the First Large-Scale Study of VHL Gene Mutation Spectrum and Genotype-Phenotype Correlationship of VHL Disease in China